| No. | Publications |
|---|---|
| 169 | Examination of Coligands in Mefloquine−Metal Complexes Reveals the Structural Determinants of Activity against Plasmodium falciparum and Schistosoma mansoniAuthors: Published date: 11 Mar 2026 |
| 168 | Bheka Thina (“Look At Us”): The Emergence of an Integrated Drug Discovery Ecosystem in South AfricaAuthors: Published date: 22 Feb 2026 |
| 167 | Small Molecule Kinase Inhibitors with In Vitro β-Hematin Formation and Plasmodium falciparum Protein Kinase G Inhibitory Activity Identified Using Machine LearningAuthors: Published date: 15 Feb 2026 |
| 166 | Blujepa for the treatment of uncomplicated urinary tract infectionsAuthors: Published date: 1 Feb 2026 |
| 165 | Optimizing Drug Discovery in Resource-Limited Settings: Multi-Parameter Optimization and Data-Driven WorkflowsAuthors: Published date: 16 Jan 2026 |
| 164 | Repositioning a Human Kinase Platelet-Derived Growth Factor Receptor Alpha Type II Inhibitor for Malaria and Inhibition of Hemozoin FormationAuthors: Published date: 26 Dec 2025 |
| 163 | A Novel Class of Orally Bioavailable Phenylglycine–Benzoxaborole Conjugates with Antimalarial Activity and Potentially Novel Mechanism of ActionAuthors: Published date: 11 Dec 2025 |
| 162 | Addressing infectious diseases in Africa by accelerating drug discovery through data scienceAuthors: Published date: 25 Nov 2025 |
| 161 | Africa finally has its own drug-regulation agencyAuthors: Published date: 13 Nov 2025 |
| 160 | Artificial intelligence coupled to pharmacometricsmodelling to tailor malaria and tuberculosis treatment in AfricaAuthors: Published date: 20 Oct 2025 |
| 159 | Optimization of 2,8-Diaryl-1,5-naphthyridines as Plasmodium falciparum Phosphatidylinositol 4-Kinase Inhibitors with Improved ADME Profiles and In Vivo EfficacyAuthors: Published date: 7 Oct 2025 |
| 157 | The Indispensable Value of Small-Molecule Antivirals in Epidemic and Pandemic PreparednessAuthors: Published date: 1 Sep 2025 |
| 156 | Novel Inhibitors of Plasmodium Phosphatidylinositol 4-kinase IIIβ with Low Propensity for Resistance: Life Cycle Stage Activity and In Vivo Efficacy in a Humanized Mouse Malaria Infection ModelAuthors: Published date: 14 Aug 2025 |
| 154 | Value Addition to African Natural Product-Based Drug Discovery InitiativesAuthors: Published date: 29 Jul 2025 |
| 153 | Maximizing Potential: Academic−Industry Collaborations in Drug DiscoveryAuthors: Published date: 3 Jul 2025 |
| 152 | Medicinal Chemistry Progression of Sapanisertib, the Anticancer and Dual Plasmodium Phosphatidylinositol 4‑Kinase Beta and cGMP-Dependent Protein Kinase Inhibitor, for MalariaAuthors: Published date: 16 May 2025 |
| 151 | Cell-Based Progression of Spiroindoline Phenotypic Hits Leads to the Identification of Compounds with Diverging Parasitological Profiles against the Human Malaria Parasite Plasmodium falciparumAuthors: Published date: 12 May 2025 |
| 150 | The ATM Kinase Inhibitor AZD0156 Is a Potent Inhibitor of Plasmodium Phosphatidylinositol 4-Kinase (PI4Kβ) and Is an Attractive Candidate for Medicinal Chemistry Optimization Against MalariaAuthors: Published date: 3 May 2025 |
| 149 | Design of Novel Mercapto-3-phenylpropanoyl Dipeptides as Dual Angiotensin-Converting Enzyme C−Domain-Selective/Neprilysin InhibitorsAuthors: Published date: 24 Mar 2025 |
| 148 | CYP1A2 contributes to the metabolism of mefloquine: Exploration using in vitro metabolism and physiologically-based pharmacokinetic modellingAuthors: Published date: 8 Mar 2025 |
| 147 | Revisiting the Plasmodium falciparum druggable genome using predicted structures and data miningAuthors: Published date: 4 Mar 2025 |
| 146 | Synthesis and SAR Studies of Acyl-Thiourea Platinum(II) Complexes Yield Analogs with Dual-Stage Antiplasmodium ActivityAuthors: Published date: 17 Feb 2025 |
| 145 | Chemistry as a Catalyst for Transforming the Health and Wealth of South AfricaAuthors: Published date: 31 Jan 2025 |
| 144 | Carboxy-Amidated AamAP1-Lys has Superior Conformational Flexibility and Accelerated Killing of Gram-Negative BacteriaAuthors: Published date: 28 Jan 2025 |
| 143 | Discovery of Non-Covalent Inhibitors for SARS-CoV‑2 PLpro: Integrating Virtual Screening, Synthesis, and Experimental ValidationAuthors: Published date: 2 Dec 2024 |
| 142 | Eliminating malaria transmission requires targeting immature and mature gametocytes through lipoidal uptake of antimalarialsAuthors: Published date: 15 Nov 2024 |
| 141 | Another decade of antimalarial drug discovery: New targets, tools and moleculesAuthors: Published date: 6 Oct 2024 |
| 140 | Total Synthesis of Tosyl-Samroiyotmycin A and Its Biological ProfilingAuthors: Published date: 30 Sept 2024 |
| 139 | Aqueous phase adsorption of phenothiazine derivative onto zinc oxide doped activated carbonAuthors: Published date: 18 Sept 2024 |
| 138 | Author Correction: Antimalarial drug discovery: progress and approachesAuthors: Published date: 13 Sept 2024 |
| 137 | Dose-fractionation studies of a Plasmodium phosphatidylinositol 4-kinase inhibitor in a humanized mouse model of malariaAuthors: Published date: 28 Aug 2024 |
| 136 | Model-Informed Approaches to Optimizing Therapeutics in the African Patient PopulationsAuthors: Published date: 21 Aug 2024 |
| 135 | The Tuberculosis Drug Candidate SQ109 and Its Analogs Have Multistage Activity against Plasmodium falciparumAuthors: Published date: 14 Aug 2024 |
| 134 | Interactions between Zoliflodacin and Neisseria gonorrhoeae Gyrase and Topoisomerase IV: Enzymological Basis for Cellular TargetingAuthors: Published date: 31 Jul 2024 |
| 133 | Ongoing Implementation and Prospective Validation of Artificial Intelligence/Machine Learning Tools at an African Drug Discovery CenterAuthors: Published date: 17 Jul 2024 |
| 132 | The dichapetalins and dichapetalin-type compounds: structural diversity, bioactivity, and future research perspectivesAuthors: Published date: 4 Jul 2024 |
| 131 | 2,8-Disubstituted-1,5-naphthyridines as Dual Inhibitors of Plasmodium falciparum Phosphatidylinositol-4-kinase and Hemozoin Formation with In Vivo EfficacyAuthors: Published date: 25 Jun 2024 |
| 130 | Characterization of antimalarial activity of artemisinin-based hybrid drugsAuthors: Published date: 20 Jun 2024 |
| 129 | hERG, Plasmodium Life Cycle, and Cross Resistance Profiling of New Azabenzimidazole Analogues of AstemizoleAuthors: Published date: 17 Apr 2024 |
| 128 | Tuberculosis treatment-shorteningAuthors: Published date: 28 Mar 2024 |
| 127 | Forging a Future Free from Neglected Tropical DiseasesAuthors: Published date: 20 Mar 2024 |
| 126 | Tips for Getting Your Manuscript Accepted into ACS Medicinal Chemistry LettersAuthors: Published date: 20 Mar 2024 |
| 125 | Unlocking Opportunities for Mycobacterium leprae and Mycobacterium ulceransAuthors: Published date: 31 Jan 2024 |
| 124 | Experimental Evaluation of a 3-D CZT Imaging Spectrometer for Potential Use in Compton-Enhanced PET ImagingAuthors: Published date: 18 Dec 2023 |
| 123 | Drug discovery in Africa tackles zoonotic and related infectionsAuthors: Published date: 18 Oct 2023 |
| 122 | First fully-automated AI/ML virtual screening cascade implemented at a drug discovery centre in AfricaAuthors: Published date: 15 Sept 2023 |
| 121 | Antimalarial drug discovery: progress and approachesAuthors: Published date: 31 Aug 2023 |
| 120 | Anti-infectives Developed as Racemic Drugs in the 21st Century: Norm or Exception?Authors: Published date: 19 Jul 2023 |
| 119 | Population Pharmacokinetic Modeling and Dose Optimization of Acetaminophen and its Metabolites Following Intravenous Infusion in Critically ill AdultsAuthors: Published date: 30 Jun 2023 |
| 118 | Developing kinase inhibitors for malaria: an opportunity or liability?Authors: Published date: 29 Jun 2023 |
| 117 | Editorial: Bacterial metabolomics approach towards antimicrobials and resistanceAuthors: Published date: 16 Jun 2023 |
| 116 | Advances in malaria pharmacology and the online guide to MALARIA PHARMACOLOGY: IUPHAR review 38Authors: Published date: 17 May 2023 |
| 115 | The first PET glimpse of a proton FLASH beamAuthors: Published date: 4 May 2023 |
| 114 | Recent developments of imidazo[1,2-a]pyridine analogues as antituberculosis agentsAuthors: Published date: 1 May 2023 |
| 113 | The implication of Mycobacterium tuberculosis-mediated metabolism of targeted xenobioticsAuthors: Published date: 28 Apr 2023 |
| 112 | Integrating Pharmacokinetic-Pharmacodynamic Modeling and Physiologically Based Pharmacokinetic Modeling to Optimize Human Dose Predictions for Plasmodium falciparum Malaria: a Chloroquine Case StudyAuthors: Published date: 3 Apr 2023 |
| 111 | A Water-Soluble Polymer-Lumefantrine Conjugate for the Intravenous Treatment of Severe MalariaAuthors: Published date: 31 Mar 2023 |
| 110 | Antimalarial Imidazopyridines Incorporating an Intramolecular Hydrogen Bonding Motif: Medicinal Chemistry and Mechanistic StudiesAuthors: Published date: 22 Mar 2023 |
| 109 | Pyrido-Dibemequine Metabolites Exhibit Improved Druglike Features, Inhibit Hemozoin Formation in Plasmodium falciparum, and Synergize with Clinical AntimalarialsAuthors: Published date: 21 Feb 2023 |
| 108 | A Series of Spiropyrimidinetriones that Enhances DNA Cleavage Mediated by Mycobacterium tuberculosis GyraseAuthors: Published date: 21 Feb 2023 |
| 107 | Identifying inhibitors of β-haematin formation with activity against chloroquine-resistant Plasmodium falciparum malaria parasites via virtual screening approachesAuthors: Published date: 14 Feb 2023 |
| 106 | The 2022 H3D Symposium: Celebrating over a Decade of African-Led Infectious Disease Drug Discovery to Enhance Global HealthAuthors: Published date: 10 Feb 2023 |
| 105 | Novel 3-Trifluoromethyl-1,2,4-oxadiazole Analogues of Astemizole with Multi-stage Antiplasmodium Activity and In Vivo Efficacy in a Plasmodium berghei Mouse Malaria Infection ModelAuthors: Published date: 12 Dec 2022 |
| 104 | 1,3-Diarylpyrazolyl-acylsulfonamides Target HadAB/BC Complex in Mycobacterium tuberculosisAuthors: Published date: 3 Nov 2022 |
| 103 | The anticancer human mTOR inhibitor sapanisertib potently inhibits multiple Plasmodium kinases and life cycle stagesAuthors: Published date: 19 Oct 2022 |
| 102 | Drug discovery research in Ghana, challenges, current efforts, and the way forwardAuthors: Published date: 15 Sept 2022 |
| 101 | Total Synthesis of the Antimycobacterial Natural Product Chlorflavonin and Analogs via a Late-Stage Ruthenium(II)-Catalyzed ortho-C(sp2)-H-HydroxylationAuthors: Published date: 26 Aug 2022 |
| 100 | Innovation Experiences from Africa-Led Drug Discovery at the Holistic Drug Discovery and Development (H3D) CentreAuthors: Published date: 18 Aug 2022 |
| 99 | Keystone Malaria Symposium 2022: a vibrant discussion of progress made and challenges ahead from drug discovery to treatmentAuthors: Published date: 21 Jul 2022 |
| 98 | Thwarting protein synthesis leads to malaria parasite paralysisAuthors: Published date: 17 Jul 2022 |
| 97 | Fostering drug discovery and development in AfricaAuthors: Published date: 15 Jul 2022 |
| 96 | Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis ActivityAuthors: Published date: 2 May 2022 |
| 95 | Spiropyrimidinetriones: a Class of DNA Gyrase Inhibitors with Activity against Mycobacterium tuberculosis and without Cross-Resistance to FluoroquinolonesAuthors: Published date: 10 Mar 2022 |
| 94 | Implications of Mycobacterium tuberculosis Metabolic Adaptability on Drug Discovery and DevelopmentAuthors: Published date: 17 Feb 2022 |
| 93 | Probing the Requirements for Dual Angiotensin-Converting Enzyme C-Domain Selective/Neprilysin InhibitionAuthors: Published date: 3 Feb 2022 |
| 92 | Structural Rigidification of N-Aryl-pyrroles into Indoles Active against Intracellular and Drug-Resistant MycobacteriaAuthors: Published date: 21 Jan 2022 |
| 91 | A d-Phenylalanine-Benzoxazole Derivative Reveals the Role of the Essential Enzyme Rv3603c in the Pantothenate Biosynthetic Pathway of Mycobacterium tuberculosisAuthors: Published date: 11 Jan 2022 |
| 90 | Quinine feverAuthors: Published date: 8 Jan 2022 |
| 89 | Identification of Phytoconstituents as Potent Inhibitors of Casein Kinase-1 Alpha Using Virtual Screening and Molecular Dynamics SimulationsAuthors: Published date: 28 Dec 2021 |
| 88 | The Artemiside-Artemisox-Artemisone-M1 Tetrad: Efficacies against Blood Stage P. falciparum Parasites, DMPK Properties, and the Case for ArtemisideAuthors: Published date: 28 Dec 2021 |
| 87 | Impact of Deleterious Mutations on Structure, Function and Stability of Serum/Glucocorticoid Regulated Kinase 1: A Gene to Diseases CorrelationAuthors: Published date: 22 Nov 2021 |
| 86 | Myricetin inhibits breast and lung cancer cells proliferation via inhibiting MARK4Authors: Published date: 9 Nov 2021 |
| 85 | MAP/Microtubule Affinity Regulating Kinase 4 Inhibitory Potential of Irisin: A New Therapeutic Strategy to Combat Cancer and Alzheimer's DiseaseAuthors: Published date: 23 Oct 2021 |
| 84 | Investigating single amino acid substitutions in PIM1 kinase: A structural genomics approachAuthors: Published date: 22 Oct 2021 |
| 83 | Population pharmacokinetic-pharmacodynamic modeling of acetaminophen in preterm neonates with hemodynamically significant patent ductus arteriosusAuthors: Published date: 30 Sept 2021 |
| 82 | Chemogenomic Fingerprints Associated with Stage-Specific Gametocytocidal Compound Action against Human Malaria ParasitesAuthors: Published date: 27 Sept 2021 |
| 81 | Editorial: Tuberculosis Drug Discovery & Development: Drug Targets, Chemical Matter, and ApproachesAuthors: Published date: 27 Sept 2021 |
| 80 | 1,3-Diarylpyrazolyl-acylsulfonamides as Potent Anti-tuberculosis Agents Targeting Cell Wall Biosynthesis in Mycobacterium tuberculosisAuthors: Published date: 20 Aug 2021 |
| 79 | Structure-Activity Relationship Studies Reveal New Astemizole Analogues Active against Plasmodium falciparum In VitroAuthors: Published date: 20 Aug 2021 |
| 78 | High-Throughput Crystallography Reveals Boron-Containing Inhibitors of a Penicillin-Binding Protein with Di- and Tricovalent Binding ModesAuthors: Published date: 2 Aug 2021 |
| 77 | Antimycobacterial Activity, Synergism, and Mechanism of Action Evaluation of Novel Polycyclic Amines against Mycobacterium tuberculosisAuthors: Published date: 9 Jul 2021 |
| 76 | Impact of single amino acid substitution on the structure and function of TANK-binding kinase-1Authors: Published date: 8 Jul 2021 |
| 75 | The Plasmodium falciparum ABC transporter ABCI3 confers parasite strain-dependent pleiotropic antimalarial drug resistanceAuthors: Published date: 7 Jul 2021 |
| 74 | Rv0684/fusA1, an Essential Gene, Is the Target of Fusidic Acid and Its Derivatives in Mycobacterium tuberculosisAuthors: Published date: 1 Jul 2021 |
| 73 | Population Pharmacokinetics and Dose Optimization of Vancomycin in Critically Ill ChildrenAuthors: Published date: 22 Jun 2021 |
| 72 | Benzoheterocyclic Oxime Carbamates Active against Mycobacterium tuberculosis: Synthesis, Structure-Activity Relationship, Metabolism, and Biology TriagingAuthors: Published date: 17 Jun 2021 |
| 71 | Structure-based investigation of MARK4 inhibitory potential of Naringenin for therapeutic management of cancer and neurodegenerative diseasesAuthors: Published date: 14 Jun 2021 |
| 70 | Toward New Transmission-Blocking Combination Therapies: Pharmacokinetics of 10-Amino-Artemisinins and 11-Aza-Artemisinin and Comparison with Dihydroartemisinin and ArtemetherAuthors: Published date: 7 Jun 2021 |
| 69 | Impact of non-synonymous mutations on the structure and function of telomeric repeat binding factor 1Authors: Published date: 13 May 2021 |
| 68 | Strategies to Combat Multi-Drug Resistance in TuberculosisAuthors: Published date: 22 Apr 2021 |
| 67 | Perspectives on RNA Vaccine Candidates for COVID-19Authors: Published date: 19 Apr 2021 |
| 66 | Antimalarial Benzimidazole Derivatives Incorporating Phenolic Mannich Base Side Chains Inhibit Microtubule and Hemozoin Formation: Structure-Activity Relationship and In Vivo Oral Efficacy StudiesAuthors: Published date: 12 Apr 2021 |
| 65 | Neurological Consequences of SARS-CoV-2 Infection and Concurrence of Treatment-Induced Neuropsychiatric Adverse Events in COVID-19 Patients: Navigating the UnchartedAuthors: Published date: 8 Mar 2021 |
| 64 | MalDA, Accelerating Malaria Drug DiscoveryAuthors: Published date: 2 Mar 2021 |
| 63 | Plasmodium Kinases as Potential Drug Targets for Malaria: Challenges and OpportunitiesAuthors: Published date: 16 Feb 2021 |
| 62 | Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite Plasmodium falciparum and Optimization EffortsAuthors: Published date: 12 Feb 2021 |
| 61 | Investigation of sphingosine kinase 1 inhibitory potential of cinchonine and colcemid targeting anticancer therapyAuthors: Published date: 10 Feb 2021 |
| 60 | Chemoprotective antimalarials identified through quantitative high-throughput screening of Plasmodium blood and liver stage parasitesAuthors: Published date: 23 Jan 2021 |
| 59 | Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?Authors: Published date: 22 Jan 2021 |
| 58 | Multistage and transmission-blocking targeted antimalarials discovered from the open-source MMV Pandemic Response BoxAuthors: Published date: 12 Jan 2021 |
| 57 | Antitubercular 2-Pyrazolylpyrimidinones: Structure-Activity Relationship and Mode-of-Action StudiesAuthors: Published date: 4 Jan 2021 |
| 56 | New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of Plasmodium Phosphatidylinositol-4-kinase and cGMP-Dependent Protein KinaseAuthors: Published date: 15 Dec 2020 |
| 55 | Tuberculosis: An Update on Pathophysiology, Molecular Mechanisms of Drug Resistance, Newer Anti-TB Drugs, Treatment Regimens and Host- Directed TherapiesAuthors: Published date: 15 Dec 2020 |
| 54 | Biological Profiling Enables Rapid Mechanistic Classification of Phenotypic Screening Hits and Identification of KatG Activation-Dependent Pyridine Carboxamide Prodrugs With Activity Against Mycobacterium tuberculosisAuthors: Published date: 7 Dec 2020 |
| 53 | Identification of 2,4-Disubstituted Imidazopyridines as Hemozoin Formation Inhibitors with Fast-Killing Kinetics and In Vivo Efficacy in the Plasmodium falciparum NSG Mouse ModelAuthors: Published date: 26 Oct 2020 |
| 52 | Structural Basis for Inhibitor Potency and Selectivity of Plasmodium falciparum Phosphatidylinositol 4-Kinase InhibitorsAuthors: Published date: 23 Sept 2020 |
| 51 | Current advances in the clinical development of anti-tubercular agentsAuthors: Published date: 21 Sept 2020 |
| 50 | Current Scenario and Future Prospect in the Management of COVID-19Authors: Published date: 9 Sept 2020 |
| 49 | Antimicrobial evaluation of neutral and cationic iridium(III) and rhodium(III) aminoquinoline-benzimidazole hybrid complexesAuthors: Published date: 30 Aug 2020 |
| 48 | Potentiation of rifampin activity in a mouse model of tuberculosis by activation of host transcription factor EBAuthors: Published date: 24 Jun 2020 |
| 47 | Synthesis, Structure-Activity Relationship, and Mechanistic Studies of Aminoquinazolinones Displaying Antimycobacterial ActivityAuthors: Published date: 30 May 2020 |
| 46 | Structure-activity relationship analyses of fusidic acid derivatives highlight crucial role of the C-21 carboxylic acid moiety to its anti-mycobacterial activityAuthors: Published date: 5 May 2020 |
| 45 | Inhibition of Resistance-Refractory P. falciparum Kinase PKG Delivers Prophylactic, Blood Stage, and Transmission-Blocking Antiplasmodial ActivityAuthors: Published date: 4 May 2020 |
| 44 | Computational model for detector timing effects in Compton-camera based prompt-gamma imaging for proton radiotherapyAuthors: Published date: 23 Apr 2020 |
| 43 | Lerisetron Analogues with Antimalarial Properties: Synthesis, Structure-Activity Relationship Studies, and Biological AssessmentAuthors: Published date: 8 Apr 2020 |
| 42 | Synthesis and evaluation of the performance of a small molecule library based on diverse tropane-related scaffoldsAuthors: Published date: 27 Mar 2020 |
| 41 | The quest for the holy grail: new antitubercular chemical entities, targets and strategiesAuthors: Published date: 17 Feb 2020 |
| 40 | Safety, Tolerability, Pharmacokinetics, and Antimalarial Activity of the Novel Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048 in Healthy VolunteersAuthors: Published date: 15 Jan 2020 |
| 39 | Plasmepsin Inhibitors in Antimalarial Drug Discovery: Medicinal Chemistry and Target Validation (2000 to Present)Authors: Published date: 9 Jan 2020 |
| 38 | Combining Stage Specificity and Metabolomic Profiling to Advance Antimalarial Drug DiscoveryAuthors: Published date: 10 Dec 2019 |
| 37 | Exploring the Antiplasmodial 2-Aminopyridines as Potential Antitrypanosomal AgentsAuthors: Published date: 1 Nov 2019 |
| 36 | Drug-resistance in Mycobacterium tuberculosis: where we standAuthors: Published date: 20 Sept 2019 |
| 35 | In Vitro Efficacies, ADME, and Pharmacokinetic Properties of Phenoxazine Derivatives Active against Mycobacterium tuberculosisAuthors: Published date: 21 Aug 2019 |
| 34 | Synergistic enhancement of beta-lactam antibiotics by modified tunicamycin analogs TunR1 and TunR2Authors: Published date: 18 Aug 2019 |
| 33 | Semisynthetic Antimycobacterial C-3 Silicate and C-3/C-21 Ester Derivatives of Fusidic Acid: Pharmacological Evaluation and Stability Studies in Liver Microsomes, Rat Plasma, and Mycobacterium tuberculosis cultureAuthors: Published date: 17 Jul 2019 |
| 32 | Novel antimycobacterial C-21 amide derivatives of the antibiotic fusidic acid: synthesis, pharmacological evaluation and rationalization of media-dependent activity using molecular docking studies in the binding site of human serum albuminAuthors: Published date: 16 Jul 2019 |
| 31 | Bioisosteric ferrocenyl aminoquinoline-benzimidazole hybrids: Antimicrobial evaluation and mechanistic insightsAuthors: Published date: 14 Jul 2019 |
| 30 | Novel and Improved Crystal Structures of H. influenzae, E. coli and P. aeruginosa Penicillin-Binding Protein 3 (PBP3) and N. gonorrhoeae PBP2: Toward a Better Understanding of β-Lactam Target-Mediated ResistanceAuthors: Published date: 14 Jul 2019 |
| 29 | Azaaurones as Potent Antimycobacterial Agents Active against MDR- and XDR-TBAuthors: Published date: 12 Jul 2019 |
| 28 | Synthesis and Structure-Activity relationship of 1-(5-isoquinolinesulfonyl)piperazine analogues as inhibitors of Mycobacterium tuberculosis IMPDHAuthors: Published date: 6 May 2019 |
| 27 | Antimalarial Pyrido[1,2- a]benzimidazole Derivatives with Mannich Base Side Chains: Synthesis, Pharmacological Evaluation, and Reactive Metabolite Trapping StudiesAuthors: Published date: 5 Jan 2019 |
| 26 | Structure-Activity Relationship Studies and Plasmodium Life Cycle Profiling Identifies Pan-Active N-Aryl-3-trifluoromethyl Pyrido[1,2- a]benzimidazoles Which Are Efficacious in an in Vivo Mouse Model of MalariaAuthors: Published date: 19 Dec 2018 |
| 25 | Multistage Antiplasmodium Activity of Astemizole Analogues and Inhibition of Hemozoin Formation as a Contributor to Their Mode of ActionAuthors: Published date: 12 Dec 2018 |
| 24 | Antiplasmodial imidazopyridazines: structure-activity relationship studies lead to the identification of analogues with improved solubility and hERG profilesAuthors: Published date: 16 Nov 2018 |
| 23 | Erratum for Brunschwig et al., "UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria"Authors: Published date: 26 Oct 2018 |
| 22 | The Next Generation Scientist program: capacity-building for future scientific leaders in low- and middle-income countriesAuthors: Published date: 12 Oct 2018 |
| 21 | Antimalarial Lead-Optimization Studies on a 2,6-Imidazopyridine Series within a Constrained Chemical Space To Circumvent Atypical Dose-Response Curves against Multidrug Resistant Parasite StrainsAuthors: Published date: 27 Sept 2018 |
| 20 | Investigating Sulfoxide-to-Sulfone Conversion as a Prodrug Strategy for a Phosphatidylinositol 4-Kinase Inhibitor in a Humanized Mouse Model of MalariaAuthors: Published date: 26 Sept 2018 |
| 19 | Defining the Determinants of Specificity of Plasmodium Proteasome InhibitorsAuthors: Published date: 16 Aug 2018 |
| 18 | UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of MalariaAuthors: Published date: 27 Jun 2018 |
| 17 | Identification, Characterization, and Optimization of 2,8-Disubstituted-1,5-naphthyridines as Novel Plasmodium falciparum Phosphatidylinositol-4-kinase Inhibitors with in Vivo Efficacy in a Humanized Mouse Model of MalariaAuthors: Published date: 12 Jun 2018 |
| 16 | Expanding Benzoxazole-Based Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitor Structure-Activity As Potential Antituberculosis AgentsAuthors: Published date: 11 May 2018 |
| 15 | Hit discovery of Mycobacterium tuberculosis inosine 5'-monophosphate dehydrogenase, GuaB2, inhibitorsAuthors: Published date: 28 Apr 2018 |
| 14 | Synthesis and biological evaluation of aryl-oxadiazoles as inhibitors of Mycobacterium tuberculosisAuthors: Published date: 23 Apr 2018 |
| 13 | Identification of Fast-Acting 2,6-Disubstituted Imidazopyridines That Are Efficacious in the in Vivo Humanized Plasmodium falciparum NODscidIL2Rγ null Mouse Model of MalariaAuthors: Published date: 19 Apr 2018 |
| 12 | 2-Mercapto-Quinazolinones as Inhibitors of Type II NADH Dehydrogenase and Mycobacterium tuberculosis: Structure-Activity Relationships, Mechanism of Action and Absorption, Distribution, Metabolism, and Excretion CharacterizationAuthors: Published date: 10 Mar 2018 |
| 11 | Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarialsAuthors: Published date: 9 Feb 2018 |
| 10 | Novel Antitubercular 6-Dialkylaminopyrimidine Carboxamides from Phenotypic Whole-Cell High Throughput Screening of a SoftFocus Library: Structure-Activity Relationship and Target Identification StudiesAuthors: Published date: 18 Nov 2017 |
| 9 | Insights into Integrated Lead Generation and Target Identification in Malaria and Tuberculosis Drug DiscoveryAuthors: Published date: 22 Jun 2017 |
| 8 | Direct Experimental Evidence for Halogen-Aryl π Interactions in Solution from Molecular Torsion BalancesAuthors: Published date: 29 Apr 2017 |
| 7 | Antischistosomal Activity of Pyrido[1,2-a]benzimidazole Derivatives and Correlation with Inhibition of β-Hematin FormationAuthors: Published date: 26 Apr 2017 |
| 6 | Intestinal Transport Characteristics and Metabolism of C-Glucosyl Dihydrochalcone, AspalathinAuthors: Published date: 31 Mar 2017 |
| 5 | Identification of a Potential Antimalarial Drug Candidate from a Series of 2-Aminopyrazines by Optimization of Aqueous Solubility and Potency across the Parasite Life CycleAuthors: Published date: 18 Oct 2016 |
| 4 | Carbon-14 radiolabeling and tissue distribution evaluation of MMV390048Authors: Published date: 21 Sept 2016 |
| 3 | Pyrrolo[3,4-c]pyridine-1,3(2H)-diones: A Novel Antimycobacterial Class Targeting Mycobacterial RespirationAuthors: Published date: 10 Nov 2015 |
| 2 | Aminopyrazolo[1,5-a]pyrimidines as potential inhibitors of Mycobacterium tuberculosis: Structure activity relationships and ADME characterizationAuthors: Published date: 3 Nov 2015 |
| 1 | Structure-Activity Relationship Studies of Orally Active Antimalarial 2,4-Diamino-thienopyrimidinesAuthors: Published date: 1 Sept 2015 |